RAB7A and melanoma: In accordance with our findings, Alonso-Curbelo et al. (2014) postulated that Rab7 is an early-induced melanoma driver and found reduced proliferation after Rab7 shRNA treatment for different melanoma lines e.g., UACC-62 or WM-164 while Rab7 shRNA treatment was much less efficient in reducing proliferation of SK-MEL-103 cells, becoming significant in the latter only after 4 days.